Yin Dawei, Tang Bin, Hu Xiaoyan, Hu Huan
Department of Anesthesiology, Huangshi Maternity and Children's Health Hospital, Affiliated Maternity and Children's Health Hospital of Hubei Polytechnic University, Huangshi Key Laboratory of Birth Defects Prevention, Huangshi, Hubei, People's Republic of China.
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China.
Drug Des Devel Ther. 2025 Jul 29;19:6357-6377. doi: 10.2147/DDDT.S519235. eCollection 2025.
Sugammadex is a novel selective relaxant binding agent for aminosteroid neuromuscular blocking agents (NMBAs). However, existing literature reveals major knowledge gaps regarding its current applications and emerging research trends. Therefore, this study employed bibliometric analysis to map the evolutionary trajectory and research frontiers in sugammadex studies over the past 15 years.
Publications on sugammadex (2009-2024) along with neostigmine studies (1993-2008) were retrieved from the Web of Science Core Collection. Data aggregation was performed using Microsoft Excel, while bibliometric visualizations were generated through the Bibliometrix package in R software. Additional network analyses were conducted using VOSviewer and CiteSpace.
The analysis encompassed 765 articles. Sugammadex-related research exhibited a notable upward trend, particularly from 2017 to 2021. The United States of America (USA) emerged as the most productive country in publication output (186 articles) and demonstrated superior quality (h-index: 16). Among institutions, Merck & Co. contributed the highest number of publications (74). Similar to neostigmine, key research areas for sugammadex have included: pharmacokinetics and pharmacodynamics, adverse reactions, clinical applications, and specific patient populations. This focus is evidenced by substantial common references and keywords.
Sugammadex surpasses neostigmine in rapidly, effectively, and safely reversing NMB induced by rocuronium/vecuronium across all depths. Its use expands to reversing residual NMB from NMBAs in various patient groups (hepatic/renal impairment, obese, neuromuscular disease, elderly, pediatric) and scenarios like difficult airways. Future research will focus on adverse reactions, effects in special populations, establishing quantitative NMB monitoring standards, and understanding NMBA antagonism failure mechanisms.
舒更葡糖钠是一种新型的甾体类神经肌肉阻滞剂（NMBAs）选择性松弛剂结合剂。然而，现有文献显示在其当前应用和新兴研究趋势方面存在重大知识空白。因此，本研究采用文献计量分析方法描绘过去15年舒更葡糖钠研究的演变轨迹和研究前沿。
从科学网核心合集检索了关于舒更葡糖钠（2009 - 2024年）以及新斯的明研究（1993 - 2008年）的出版物。使用Microsoft Excel进行数据汇总，同时通过R软件中的Bibliometrix包生成文献计量可视化图。使用VOSviewer和CiteSpace进行额外的网络分析。
该分析涵盖765篇文章。舒更葡糖钠相关研究呈现出显著的上升趋势，尤其是在2017年至2021年期间。美国是发表论文数量最多的国家（186篇），且质量上乘（h指数：16）。在机构方面，默克公司的出版物数量最多（74篇）。与新斯的明类似，舒更葡糖钠的关键研究领域包括：药代动力学和药效学、不良反应、临床应用以及特定患者群体。大量的共同参考文献和关键词证明了这一重点。
在快速、有效且安全地逆转罗库溴铵/维库溴铵在所有深度诱导的神经肌肉阻滞方面，舒更葡糖钠优于新斯的明。其用途扩展到逆转各种患者群体（肝/肾功能损害、肥胖、神经肌肉疾病、老年人、儿童）以及困难气道等情况下NMBAs残留的神经肌肉阻滞。未来的研究将集中在不良反应、特殊人群中的作用、建立定量神经肌肉阻滞监测标准以及了解神经肌肉阻滞剂拮抗失败机制。
